[{"address1": "350 Queen Street", "address2": "Level 17", "city": "Melbourne", "state": "VIC", "zip": "3000", "country": "Australia", "phone": "61 3 9123 1140", "fax": "61 3 9473 2555", "website": "https://www.ampliatx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Amplia Therapeutics Limited, a pharmaceutical company, focuses on the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline includes AMP945, an inhibitor of FAK that has completed Phase I clinical trial for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases; and AMP886 for treating acute myeloid leukemia and various solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.", "age": 58, "title": "CEO, MD & Director", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 256437, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tim  Luscombe B.Com., C.A.", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rhiannon  Jones B.Sc., Ph.D.", "title": "Chief Operating Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD", "age": 63, "title": "Company Secretary", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 52038, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "open": 0.0979, "dayLow": 0.0979, "dayHigh": 0.0979, "regularMarketOpen": 0.0979, "regularMarketDayLow": 0.0979, "regularMarketDayHigh": 0.0979, "beta": 0.708, "volume": 31000, "regularMarketVolume": 31000, "averageVolume": 13840, "averageVolume10days": 5050, "averageDailyVolume10Day": 5050, "bid": 0.0734, "ask": 0.0996, "marketCap": 24457024, "fiftyTwoWeekLow": 0.025, "fiftyTwoWeekHigh": 0.105, "priceToSalesTrailing12Months": 5.492576, "fiftyDayAverage": 0.06372, "twoHundredDayAverage": 0.052815, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 22374480, "profitMargins": -1.01139, "floatShares": 167251533, "sharesOutstanding": 274798016, "heldPercentInsiders": 0.22569, "heldPercentInstitutions": 0.17772, "bookValue": 0.059, "priceToBook": 1.5084746, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -4503453, "trailingEps": -0.02, "enterpriseToRevenue": 5.025, "enterpriseToEbitda": -4.907, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "INNMF", "underlyingSymbol": "INNMF", "shortName": "Amplia Therapeutics Ltd.", "longName": "Amplia Therapeutics Limited", "firstTradeDateEpochUtc": 1610116200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cd1e35ee-43dd-36b8-b44b-e80a0991f1dd", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.089, "recommendationKey": "none", "totalCash": 3385310, "totalCashPerShare": 0.012, "ebitda": -4559597, "totalDebt": 1586568, "quickRatio": 1.928, "currentRatio": 1.984, "totalRevenue": 4452742, "debtToEquity": 13.895, "revenuePerShare": 0.023, "returnOnAssets": -0.17038, "returnOnEquity": -0.33048, "freeCashflow": -3590132, "operatingCashflow": -5127182, "grossMargins": 0.90073997, "ebitdaMargins": -1.024, "operatingMargins": -1.70076, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-08-29"}]